These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 28477089)

  • 1. The phosphodiesterase-4 inhibitor roflumilast decreases ethanol consumption in C57BL/6J mice.
    Liu X; Hao PD; Yang MF; Sun JY; Mao LL; Fan CD; Zhang ZY; Li DW; Yang XY; Sun BL; Zhang HT
    Psychopharmacology (Berl); 2017 Aug; 234(16):2409-2419. PubMed ID: 28477089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of phosphodiesterase-4 decreases ethanol intake in mice.
    Hu W; Lu T; Chen A; Huang Y; Hansen R; Chandler LJ; Zhang HT
    Psychopharmacology (Berl); 2011 Nov; 218(2):331-9. PubMed ID: 21509503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct Inhibitory Effect of the PDE4 Inhibitor Roflumilast on Neutrophil Migration in Chronic Obstructive Pulmonary Disease.
    Dunne AE; Kawamatawong T; Fenwick PS; Davies CM; Tullett H; Barnes PJ; Donnelly LE
    Am J Respir Cell Mol Biol; 2019 Apr; 60(4):445-453. PubMed ID: 30395484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Nonhuman Primate PET Study: Measurement of Brain PDE4 Occupancy by Roflumilast Using (R)-[
    Takano A; Uz T; Garcia-Segovia J; Tsai M; Lahu G; Amini N; Nakao R; Jia Z; Halldin C
    Mol Imaging Biol; 2018 Aug; 20(4):615-622. PubMed ID: 29441434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways.
    Kwak HJ; Park KM; Choi HE; Chung KS; Lim HJ; Park HY
    Cell Signal; 2008 May; 20(5):803-14. PubMed ID: 18276108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation of ethanol abstinence-induced anxiety- and depressive-like behavior by the phosphodiesterase-4 inhibitor rolipram in rodents.
    Gong MF; Wen RT; Xu Y; Pan JC; Fei N; Zhou YM; Xu JP; Liang JH; Zhang HT
    Psychopharmacology (Berl); 2017 Oct; 234(20):3143-3151. PubMed ID: 28748375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterase-4 inhibition augments human lung fibroblast vascular endothelial growth factor production induced by prostaglandin E2.
    Ikari J; Michalski JM; Iwasawa S; Gunji Y; Nogel S; Park JH; Nelson AJ; Farid M; Wang X; Schulte N; Basma H; Toews ML; Feghali-Bostwick C; Tenor H; Liu X; Rennard SI
    Am J Respir Cell Mol Biol; 2013 Oct; 49(4):571-81. PubMed ID: 23656623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation.
    Konrad FM; Bury A; Schick MA; Ngamsri KC; Reutershan J
    PLoS One; 2015; 10(4):e0121725. PubMed ID: 25909327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner.
    Lehrke M; Kahles F; Makowska A; Tilstam PV; Diebold S; Marx J; Stöhr R; Hess K; Endorf EB; Bruemmer D; Marx N; Findeisen HM
    J Mol Cell Cardiol; 2015 Apr; 81():23-33. PubMed ID: 25640159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The phosphodiesterase-4 (PDE4) inhibitor rolipram decreases ethanol seeking and consumption in alcohol-preferring Fawn-Hooded rats.
    Wen RT; Zhang M; Qin WJ; Liu Q; Wang WP; Lawrence AJ; Zhang HT; Liang JH
    Alcohol Clin Exp Res; 2012 Dec; 36(12):2157-67. PubMed ID: 22671516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses.
    Vanmierlo T; Creemers P; Akkerman S; van Duinen M; Sambeth A; De Vry J; Uz T; Blokland A; Prickaerts J
    Behav Brain Res; 2016 Apr; 303():26-33. PubMed ID: 26794595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of rolipram and roflumilast, phosphodiesterase-4 inhibitors, on hypertension-induced defects in memory function in rats.
    Jabaris SG; Sumathy H; Kumar RS; Narayanan S; Thanikachalam S; Babu CS
    Eur J Pharmacol; 2015 Jan; 746():138-47. PubMed ID: 25446433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts.
    Togo S; Liu X; Wang X; Sugiura H; Kamio K; Kawasaki S; Kobayashi T; Ertl RF; Ahn Y; Holz O; Magnussen H; Fredriksson K; Skold CM; Rennard SI
    Am J Physiol Lung Cell Mol Physiol; 2009 Jun; 296(6):L959-69. PubMed ID: 19304913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species.
    Rutter AR; Poffe A; Cavallini P; Davis TG; Schneck J; Negri M; Vicentini E; Montanari D; Arban R; Gray FA; Davies CH; Wren PB
    J Pharmacol Exp Ther; 2014 Jul; 350(1):153-63. PubMed ID: 24784567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer's Disease: A Preclinical Study in APP/PS1 Transgenic Mice.
    Wang H; Zhang FF; Xu Y; Fu HR; Wang XD; Wang L; Chen W; Xu XY; Gao YF; Zhang JG; Zhang HT
    Int J Neuropsychopharmacol; 2020 Dec; 23(10):700-711. PubMed ID: 32645141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
    Davis TG; Peterson JJ; Kou JP; Capper-Spudich EA; Ball D; Nials AT; Wiseman J; Solanke YE; Lucas FS; Williamson RA; Ferrari L; Wren P; Knowles RG; Barnette MS; Podolin PL
    J Pharmacol Exp Ther; 2009 Sep; 330(3):922-31. PubMed ID: 19498103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of phosphodiesterase type 4 decreases stress-induced defecation in rats and mice.
    Barone FC; Barton ME; White RF; Legos JJ; Kikkawa H; Shimamura M; Kuratani K; Kinoshita M
    Pharmacology; 2008; 81(1):11-7. PubMed ID: 17726343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.
    Growcott EJ; Spink KG; Ren X; Afzal S; Banner KH; Wharton J
    Respir Res; 2006 Jan; 7(1):9. PubMed ID: 16423283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
    Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
    Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice.
    Rieder F; Siegmund B; Bundschuh DS; Lehr HA; Endres S; Eigler A
    PLoS One; 2013; 8(2):e56867. PubMed ID: 23468885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.